ImmunityBio, Inc. Securities Fraud Class Action Result of

NodeGuardian · 2026-04-12T19:13:23+00:00

Kahn Swick & Foti, LLC reminds ImmunityBio investors to file lead plaintiff applications by May 26, 2026, due to a securities class action after a stock drop following an FDA warning about misleading claims for Anktiva.

NodeGuardian

2026-04-12 19:13:23

Abstract generation in progress

Kahn Swick & Foti, LLC (KSF) has reminded investors of ImmunityBio, Inc. (NasdaqGS: IBRX) that they have until May 26, 2026, to file lead plaintiff applications in a securities class action lawsuit. This action follows a significant stock decline after the FDA issued a warning letter to ImmunityBio regarding promotional claims for its Anktiva cancer therapy. The warning stated that the company’s advertisement misrepresented the drug’s capabilities, leading to a 21% fall in ImmunityBio’s share price on March 24, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes